三例急性髓系白血病患者基因表达谱的演变  

Evolution of gene expression profile in 3 cases of acute myeloid leukemia

作　　者：唐加明[1] 孟凡义[1] 马文丽[2] 

机构地区：[1]南方医科大学附属南方医院血液科 [2]南方医科大学基因工程研究所

出　　处：《中华血液学杂志》2005年第11期653-655,共3页Chinese Journal of Hematology

基　　金：广东省自然科学基金资助项目(A32892);广东省科技计划攻关课题资助项目(B30202)

摘　　要：目的研究急性髓系白血病(AML)患者初诊与复发时的基因表达谱差异,探讨难治性AML的发病机制。方法应用Agilent Human1B寡核苷酸基因芯片,动态检测了3例AML-M2a患者初诊、复发时骨髓单个核细胞的基因表达谱差异。结果在检测的20173个基因中,有10个基因在3例患者初诊、复发时共同差异表达,其中7个基因在复发时均共同上调,3个基因在复发时均表现下调。结论DAPK1等10个基因的表达变化可能与AML-M2a发病和复发有关,这些新基因的发现可能对早期诊断难治性AML具有重要价值,同时为难治性AML提供新的治疗靶点。Objective To investigate the mechanism of refractoriness of acute myeloid leukemia （AML） by studying the changes of gene mRNA expression from primary diagnosis to relapsed disease in AML. Methods Differences in gene expression profile of bone marrow mononuelear cells were compared between primary diagnosis and relapsed/refractory disease in 3 patients with M2a subtype of AML using Agilent human IB 60mer oligonueleotide mieroarray. Results Common alterations were found in 10 genes among the 20173 genes tested at relapsed/refractory disease as compared with that at primary diagnosis in 3 patients. Of these 10 genes, 7 were up-regulated while 3 down-regulated at relapse in all the 3 patients. Conclusion Development of relapsed/refractory disease in AML-M2a might be associated with the mRNA expression changes in the 10 genes tested including DAPKI. The alteration of these genes may be indications for the early diagnosis of refractoriness of AML, and these genes might provide new therapeutic targets for the treatment of refractory AML.

关 键 词：急性髓系白血病 基因表达谱 病理机制 寡核苷酸 基因芯片技术 

分 类 号：R733.7[医药卫生—肿瘤]